The Improvement Effect of Magnolia officinalis Oil Extract on Non-alcoholic Fatty Liver Disease and Its Mechanism of Regulating Inflammatory Pathways and Oxidative Stress in HepG2 cells

References

[1] Ji L, Li Q, He Y, Zhang X, Zhou Z, Gao Y, et al. Therapeutic potential of traditional Chinese medicine for the treatment of NAFLD: A promising drug Potentilla discolor Bunge. Acta Pharmaceutica Sinica B. 2022;12(9):3529-47.

[2] Tilg H, Targher G. NAFLD-related mortality: simple hepatic steatosis is not as ‘benign’ as thought. Gut. 2021;70(7):1212-3.

[3] Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577-86.

[4] Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysi-ology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63.

[5] Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686-90.

[6] Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019;76:99-128.

[7] Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med. 2009;87:679-95.

[8] Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther. 2017;34:1291-326.

[9] Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res. 2009;48(1):1-26.

[10] Shao M, Ye Z, Qin Y, Wu T. Abnormal metabolic processes involved in the pathogenesis of non-alcoholic fatty liver disease. Exp Ther Med. 2020;20(5):1-1.

[11] Deng Y, Tang K, Chen R, Nie H, Liang S, Zhang J, et al. Berberine attenuates hepatic oxidative stress in rats with non-alcoholic fatty liver disease via the Nrf2/ARE signalling pathway. Exp Ther Med. 2019;17(3):2091-8.

[12] Schug TT, Li X. Sirtuin 1 in lipid metabolism and obesity. Ann Med. 2011;43(3):198-211.

[13] Guo X, Yin X, Liu Z, Wang J. Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment. Int J Mol Sci. 2022;23(24):15489.

[14] Sumida Y, Niki E, Naito Y, Yoshikawa T. Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic Res. 2013;47(11):869-80.

[15] Yahoo N, Dudek M, Knolle P, Heikenwälder M. Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation.

[16] Pierantonelli I, Svegliati-Baroni G. Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH. Transplantation. 2019;103(1):e1-e13.

[17] Scorletti E, Carr RM. A new perspective on NAFLD: Focusing on lipid droplets. J Hepatol. 2022;76(4):934-45.

[18] Wen W, Wu P, Zhang Y, Chen Z, Sun J, Chen H. Comprehensive analysis of NAFLD and the therapeutic target identified. Front Cell Dev Biol. 2021;9:704704.

[19] Michelotti A, de Scordilli M, Palmero L, Guardascione M, Masala M, Roncato R, et al. NAFLD-related hepatocarcinoma: the malignant side of metabolic syndrome. Cells. 2021;10(8):2034.

[20] Rinaldi L, Pafundi PC, Galiero R, Caturano A, Morone MV, Silvestri C, et al. Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A narrative review. Antioxidants. 2021;10(2):270.

[21] Zarghamravanbakhsh P, Frenkel M, Poretsky L. Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). Metab Open. 2021;12:100149.

[22] Hughey CC, Puchalska P, Crawford PA. Integrating the contributions of mitochondrial oxidative metabolism to lipotoxicity and inflammation in NAFLD pathogenesis. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867(11):159209.

[23] Naik A, Belič A, Zanger UM, Rozman D. Molecular interactions between NAFLD and xenobiotic metabolism. Front Genet. 2013;4:2.

[24] Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(39):14205.

[25] Klisic A, Kavaric N, Ninic A, Kotur-Stevuljevic J. Oxidative stress and cardiometabolic biomarkers in patients with non-alcoholic fatty liver disease. Sci Rep. 2021;11(1):18455.

[26] Liu F, Zhu S, Xiong Z. Anti-anxiety and antidepressant properties of bioactive neolignans derived from Magnolia officinalis.

[27] Rodriguez-Mateos A, Feliciano RP, Boeres A, Weber T, Dos Santos CN, Ventura MR, et al. Cranberry (poly) phenol metabolites correlate with improvements in vascular function: A double-blind, randomized, controlled, dose-response, crossover study. Mol Nutr Food Res. 2016;60(10):2130-40.

[28] Luo H, Wu H, Yu X, Zhang X, Lu Y, Fan J, et al. A review of the phytochemistry and pharmacological activities of Magnoliae officinalis cortex. J Ethnopharmacol. 2019;236:412-42.

[29] Khan A, Ross HM, Parra NS, Chen SL, Chauhan K, Wang M, et al. Risk prevention and health promotion for non-alcoholic fatty liver diseases (NAFLD). Livers. 2022;2(4):264-82.

[30] Liang Z, Chen X, Shi J, Hu H, Xue Y, Ung COL. Efficacy and safety of traditional Chinese medicines for non-alcoholic fatty liver disease: a systematic literature review of randomized controlled trials. Chin Med. 2021;16:1-38.

[31] Seo MS, Hong SW, Yeon SH, Kim YM, Um KA, Kim JH, et al. Magnolia officinalis attenuates free fatty acid-induced lipogenesis via AMPK phosphorylation in hepatocytes. J Ethnopharmacol. 2014;157:140-8.

[32] Tian Y, Feng H, Han L, Wu L, Lv H, Shen B, et al. Magnolol alleviates inflammatory responses and lipid accumulation by AMP-activated protein kinase-dependent peroxisome proliferator-activated receptor α activation. Front Immunol. 2018;9:147.

[33] Xie NA, Hu C, Guo A, Liang H, Du P, Yin G. Metabolic regulation of magnolol on the nuclear receptor, liver X receptor. Exp Ther Med. 2015;9(5):1827-30.

[34] Nassir F, Rector RS, Hammoud GM, Ibdah JA. Pathogenesis and prevention of hepatic steatosis. 2015 Mar.

[35] Anggreini P, Kuncoro H, Sumiwi SA, Levita J. Role of the AMPK/SIRT1 pathway in non-alcoholic fatty liver disease. Mol Med Rep. 2023;27(2):1-11.